

Optimization of Phenyl Indole Inhibitors of the AAA+ ATPase p97

Matthew G. LaPorte,[†] James C. Burnett,^{†,‡} Raffaele Colombo,[†] Stacie L. Bulfer,[§] Celeste Alvarez,^{†,||} Tsui-Fen Chou,[⊥] R. Jeffrey Neitz,[§] Neal Green,[#] William J. Moore,[#] Zhizhou Yue,[†] Shan Li,[⊥] Michelle R. Arkin,^{*,§} Peter Wipf,^{*,†,||} and Donna M. Huryn^{*,†,||}

[†]University of Pittsburgh Chemical Diversity Center, University of Pittsburgh, Pittsburgh, Pennsylvania 15260, United States

[‡]Computational Drug Development Group, Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland 20892, United States

[§]Department of Pharmaceutical Chemistry, Small Molecule Discovery Center, University of California, San Francisco, California 94158, United States

^{||}Department of Pharmaceutical Sciences, University of Pittsburgh, Pittsburgh, Pennsylvania 15260, United States


[⊥]Division of Medical Genetics, Department of Pediatrics, Harbor–UCLA Medical Center and Los Angeles Biomedical Research Institute, Torrance, California 90502, United States

[#]Leidos Biomedical Research, Inc., Frederick, Maryland 21702, United States

S Supporting Information

ABSTRACT: Optimization of the side-chain of a phenyl indole scaffold identified from a high-throughput screening campaign for inhibitors of the AAA+ ATPase p97 is reported. The addition of an *N*-alkyl piperazine led to high potency of this series in a biochemical assay, activity in cell-based assays, and excellent pharmaceutical properties. Molecular modeling based on a subsequently obtained cryo-EM structure of p97 in complex with a phenyl indole was used to rationalize the potency of these allosteric inhibitors.

KEYWORDS: AAA+ ATPase, p97, allosteric inhibitor, protein homeostasis modulator, anticancer, phenyl indole



The AAA+ (ATPase associated with various cellular activities) p97 is a hexameric, multidomain protein that plays a key role in protein homeostasis. Energy from the hydrolysis of ATP is mechanically relayed by p97 for the extraction of polypeptides from membranes, the ribosome or DNA, facilitating polypeptide degradation by the proteasome. In addition, p97 is hypothesized to play a role in other protein degradation pathways, including autophagy.^{1,2} Its essential role in protein homeostasis and the clinical success of proteasome inhibitors suggest the potential for targeting certain cancers with p97 inhibitors. Toward this end, a number of small molecule inhibitors of p97 have been reported to show promising antiproliferative effects.^{3–10} One ATP-competitive active site inhibitor, CB-5083, advanced to Phase I clinical trials for multiple myeloma and advanced solid tumors but was recently discontinued due to off-target retinal toxicity related to inhibition of PDE6.^{10–12}

As part of our efforts to identify small molecule allosteric inhibitors of p97,^{9,13,14} we embarked on a medicinal chemistry program to optimize a 2-phenyl indole scaffold discovered via a high-throughput screening (HTS) effort.¹⁵ At the time our work was conducted, no structural information on the compound's binding site was available, although it was determined to bind to an allosteric site.¹⁵ A structure–activity relationship (SAR) study illustrated the importance of the indole moiety for

potency.^{13,14} In this Letter, we disclose additional SAR data and the optimization of the flexible side-chain, as well as biological characterization of key analogs.

Compound **1** (Figure 1 and Table 1) is representative of early active compounds in the phenyl indole series. Compound **1** inhibited the ATPase activity of p97 with an $IC_{50} = 2.4 \mu M$ at low ATP concentration ($20 \mu M$). At higher ATP concentrations ($100 \mu M$), the IC_{50} improved to $0.99 \mu M$, indicating an



























Figure 1. First-generation phenyl indole inhibitor **1** and areas of focused SAR explorations.

Received: August 15, 2018

Accepted: September 18, 2018

Published: September 18, 2018

Table 1. p97 Inhibitory Activity of Phenyl Indole^a



Compound	R ₁	R ₂	p97 IC ₅₀ (μM) (n)	Compound	R ₁	R ₂	p97 IC ₅₀ (μM) (n)
1	H		0.99±0.56 (44)	15	F		0.80±0.34 (5)
5	H		2.6±0.66 (2)	16	F		0.19±0.15 (4)
6	H		1.05±1.2 (4)	17	F		0.05±0.04 (12)
7	H		1.06±0.25 (2)	18	F		0.18±0.06 (5)
8	H		0.33±0.14 (4)	19	F		4.26±1.15 (5)
9	H		0.28±0.12 (5)	20	F		1.13±0.17 (2)
10	H		0.20±0.09 (4)	21	F		4.76±2.13 (5)
11	H		0.16±0.10 (17)	22	F		19.0 (1)
12	H		0.21±0.12 (13)	23	F		0.02±0.02 (15)
13	H		0.38±0.05 (2)	24	F		0.10±0.09 (5)
14	F		0.07±0.11 (65)	25	F		0.09±0.08 (6)

^aAssay conditions: ADP-Glo with 20 nM WT p97 in the presence of 100 μM ATP. *n* denotes number of independent replicates, each assayed in duplicate or triplicate. In the same assay, the allosteric p97 inhibitor, NMS-873,⁸ exhibited an IC₅₀ = 11 nM ± 4.9 (*n* = 13).

uncompetitive binding mechanism.¹⁵ Properties (MW, CLogP, tPSA; ChemDraw) of **1** were all in the drug-like range.

For further optimization, we used an approach that kept the 2-(3-(piperidin-1-yl)phenyl)-1*H*-indole scaffold constant and varied the amine side-chain (Scheme 1). Our synthetic strategy, which focused on late-stage diversification, relied on previously optimized Buchwald–Hartwig couplings of 3-bromo-2-phenyl indoles (**2**).^{13,14,16–18} The intermediate, **3**, was used for rapid further diversification via reductive aminations¹⁹ to afford, in some cases after additional modifications, final products of general structure **4**. An alternative strategy relied on direct coupling of an intact side-chain (or a related analog) with **2** to generate **4**.

Scheme 1. General Synthesis of Phenyl Indoles Using Late-Stage Diversification Strategies



The first rounds of SAR were generated from the unsubstituted 2-phenyl indole core and explored a wide array of side-chain amines that varied the terminal group as well as the linker to the piperidine. Replacement of the terminal triazole in **1** with a phenyl group, resulting in analog **5**, led to a loss of potency, indicating the requirement for a polar group at this position. Replacement with a pyridine (**6**) restored activity to near original levels.

The length of the linker appeared to be insignificant, as the 1-carbon linker (**7**) possessed equivalent potency to the 2-carbon analog in this series. Replacement of the aromatic heterocycle with a piperazine group provided a first significant (~3-fold) improvement in potency (**8**; $IC_{50} = 330$ nM) compared to compound **1**.²⁰ Further functionalization by capping the terminal nitrogen with an aliphatic substituent (e.g., Me, Et, *i*Pr, *t*Bu; **9–12**), provided another boost in potency. In these examples, the general trend was that greater lipophilicity seemed to correlate with improved potency, with *i*Pr exhibiting 160 nM potency. In contrast to compounds **6** and **7**, the length of the linker between the piperidine and the terminal moiety modestly affected potency: a 3-carbon linker (**13**) was ~2-fold less potent than its 2-carbon homologue **11**.

Combining the preferred 5-F indole^{14,16} with the N-*i*Pr piperazine afforded **14**, the first analog with potency below 100 nM ($IC_{50} = 70$ nM). Previous SAR data¹³ indicated that the indole moiety was highly sensitive to modification, and a cryo-EM co-structure¹⁶ and extensive molecular modeling¹⁴ showed the indole deeply embedded in an allosteric binding site in p97's D2 domain, located very near the D1–D2 interface, with the fluorine atom engaging in key interactions with surrounding residues.^{14,16} Given the importance of the 5-fluoroindole to binding and potency, our next iterations maintained this feature and explored additional amine groups that contained a N-*i*Pr moiety (see SI).

The terminal amine in the piperazine moiety contributed to potency, as the truncated dimethyl amino analog **15**, while maintaining some activity ($IC_{50} = 800$ nM), was >10-fold less potent than **14**. Modulation of the piperazine nitrogen's basicity by introducing a carbonyl group into a 3-carbon linker as in **16** was tolerated, but decreased potency compared to **14**. While **16** ($IC_{50} = 190$ nM) was slightly more potent than **13** ($IC_{50} = 380$ nM), we attributed this difference to the presence of the potency-enhancing 5-F indole moiety rather than a preference for the modified linker. We concluded that the length of the linker was not critical to potency and that the pK_a of the internal piperazine nitrogen could be manipulated without detriment to biological activity. Taking this information into account, we attempted to simultaneously constrain the conformation of the flexible side-chain and reduce the number of basic nitrogen atoms. This led to the design of analogs such as **17**, containing an amine-linked bis-piperidine side-chain. This compound exhibited strong inhibition of p97 ($IC_{50} = 50$ nM) and was somewhat more potent than compounds containing a flexible linker, such as **14**. While we had no data to suggest specific liabilities, the elimination of a basic nitrogen was anticipated to address potential liabilities such as hERG receptor binding and efflux. To further explore this truncated scaffold, we replaced the internal piperidine with *cis*- and *trans*-cyclohexane groups (see SI). The *trans*-analog **18** retained activity toward p97, albeit ~3–4-fold less than the piperidine **17**. In contrast, the *cis*-isomer **19** was >20-fold less potent compared to the *trans*-isomer and >100-fold less potent than **17**, indicating a significant conformational preference. Further shortening and constraining the side-

chain by eliminating the nitrogen linkage (e.g., spiro analog **20**; piperidine-piperazine **21**; and fused bicyclo[3.3.0] ring system **22**) was not productive. These compounds inhibited p97 in the micromolar range.

As an alternate approach to conformational constraint, we incorporated small cyclic moieties as “kinks” into the flexible linker. This strategy led to some of the most potent analogs in this series. Cyclobutane **23** inhibited p97 with an $IC_{50} = 20$ nM, i.e., over ten times more potent than the parent analog **9**. Based on SAR trends, this difference could not be attributed solely to the presence of the 5-F indole in **23**. Unlike the flexible linker series (e.g., **9–11**), within this subseries, the N-Me piperazine terminus (**23**) was 5-fold more potent than the N-*i*Pr analog (**24**). The oxetane analog **25** ($IC_{50} = 90$ nM) was similar in potency to the cyclobutane **24**.

To develop structure-based hypotheses to rationalize the biochemical activity of this series, we utilized a recently reported cryo-EM costructure of **14** bound to p97; however, while strong electron-density for the phenyl-indole component of the inhibitor was observed in this structure, there was no density detected for the conformationally flexible side-chain.¹⁶ As shown in Figure 2a, the side-chain in the cryo-EM model was positioned extending out of the allosteric binding cleft and directly into solvent, making no contacts with the protein.¹⁶ This binding mode was inconsistent with the side-chain SAR, which indicated a preference for specific, basic groups at this position




Figure 2. (a) Representation of cryo-EM structure of **14** (carbon = magenta; nitrogen = blue; fluorine = light blue; key hydrogens = white; yellow dashes = H-bonds) bound to p97 at an allosteric site in the D2 domain.¹⁶ The phenyl indole binds in a deep pocket, but the side-chain points directly into solvent and engages in no contacts with protein residues. (b) Molecular modeling-derived binding mode that accounts for side-chain SAR. Key inhibitor (**14**) side-chain–protein interactions include H-bonds (yellow dashes) with Gln494, Glu498, Glu534, and Cys535, as well as solvent shielding of the terminal *i*Pr group by the side-chain indole of Trp476.

(e.g., piperazine preferred over pyridine and phenyl, as in **8** vs **6**, **5**), as well as a preference for lipophilic groups at the piperazine terminus (e.g., ethyl, *i*Pr, *t*Bu: **10–12** vs H, Me: **8**, **9**). We therefore developed a binding model that is consistent with the available SAR (Figure 2b). Placing the piperidine ring in a chair conformation (vs the twist chair conformation in the cryo-EM costructure) allows the basic side-chain of **14** to be oriented toward the protein and to engage in multiple hydrogen bonds, instead of extending out into solvent. Favorable interactions develop between (1) the terminal piperazine nitrogen atom and the Glu534 carboxylate, (2) the internal piperazine nitrogen atom and the side-chain amide carbonyl of Gln494, (3) the secondary amine and Glu498, and (4) the piperidine ring nitrogen atom (an aniline) and the thiol of Cys535 (an interaction also observed in the twist chair conformation). Using this refined model, we were able to rationalize much of the SAR, particularly that of the side-chain.

Figure 3 shows the proposed binding modes of *trans*- and *cis*-cyclohexanes **18** and **19**. The *trans*-orientation in **18** results in a




Figure 3. Molecular modeling comparison of the binding modes of **18** (a, carbon = cyan) and **19** (b, carbon = orange); yellow dashes = H-bond; red dashes and spheres = unfavorable interactions. (a) Side-chain of **18** retains two H-bonds to Glu498 and Glu534, the cyclohexyl group engages in hydrophobic interactions with Val493 and Ile531, and the terminal *i*Pr group is located near, and solvent shielded by, the side-chain indole moiety of Trp476. (b) In contrast, in the model of the *cis*-isomer (**19**) the H-bond to Glu498 is lost; unfavorable interactions (red dashes and spheres) between the secondary nitrogen and hydrophobic side chains Val493 and Ile531 are observed, and the cyclohexyl and *i*Pr groups are significantly more solvent exposed.

favorable binding mode for the side-chain component; hydrogen bonds with acidic residues Glu498 and Glu534 are maintained, and the cyclohexyl component engages in hydrophobic contacts with side-chains of Val493 and Ile531. Additionally, the *i*Pr group orients away from the solvent

toward the aromatic indole side-chain of residue Trp476. In contrast, binding of the *cis*-isomer **19** results in a significantly more solvent-exposed side-chain orientation that forces the cyclohexyl and *i*Pr groups toward the solvent, an energetically unfavorable pose. Moreover, the secondary nitrogen atom engages in unfavorable hydrophobic–polar clashes with the side-chains of residues Val493 and Ile531. Finally, the constrained orientation of the *cis*-isomer results in the loss of a hydrogen bond with Glu498. The increased potency of **23** compared to compounds resembling **14** can be rationalized by the binding pose in Figure 4, and the observation that the kinked




Figure 4. Predicted binding mode of **23** (carbon = pink; yellow dashes = H-bonds). Like other inhibitors of this chemotype, the side-chain binds down the helix 16/17 interface and engages in multiple hydrogen bonds with side-chain residues. However, unlike the more flexible parent **14**, the cyclobutyl moiety of **23** binds more deeply in a hydrophobic pocket at the helical interface. As a result, (1) new H-bond patterns are formed with the amide side-chains of Gln490 and 494 and (2) the cyclobutyl moiety engages in closer, more favorable hydrophobic contacts with the side-chains of Val493 and Ile531, and (3) the terminal piperazine nitrogen engages in a cation– π interaction with the side-chain indole of Trp476 (purple dash with terminal, semi-transparent sphere).

side-chain is embedded more deeply into the p97 helix 16–17 interface than the straight-chain analogs, and more fully occupies a hydrophobic pocket formed by Val493, Ile531 (Figure 4), and, to a lesser degree, Leu 527. We hypothesize that desolvation of the cyclobutyl group drives this deeper binding mode. Interestingly, the more buried binding mode of the side-chain of **23** results in the loss of the H-bond with Glu498 predicted for **14** and a weakening of the H-bond with Glu534 that is observed for **14** (Figure 2b). Rather, the side-chain of **23** engages in H-bonds with the amide side-chains of Gln490 and 494 and forms a favorable cation– π interaction with the side-chain of Trp476. As noted above, within this *gem*-disubstituted cyclobutane subseries, *N*-Me piperazine is favored over the *N*-*i*Pr analog (**23** vs **24**), in contrast to other members of the class (e.g., **9** vs **11**), where the larger group is preferred. We hypothesize that the presence of the smaller *N*-Me substituent is more sterically compatible with the formation of the cation– π interaction than larger terminal moieties.

The biochemical potencies of compounds **17** and **23** compare favorably to another allosteric inhibitor of p97, NMS-873 (IC_{50} = 11 nM)⁸ in side-by-side comparisons. However, the physical properties of the phenyl indoles are superior. Specifically, the aqueous (pH 7.4) solubility (>300 μ M) and half-life in *in vitro* metabolic stability assays ($t_{1/2}$ > 270 min) in human (HLM) and mouse liver microsomes (MLM) (Table 2) of **17** and **23** are

Table 2. Characterization of Compounds 17 and 23 and Comparison to NMS-873

properties	17	23	NMS-873
p97 IC ₅₀ (nM)	50	20	11
solubility (μ M)	380	330	86
HLM (<i>t</i> _{1/2} , min)	569	475	<10
MLM (<i>t</i> _{1/2} , min)	386	277	<10
Ub ^{G76V} -GFP EC ₅₀ (μ M)			
1 h	19	15	1.4
6 h	>40	>40	2.1
NCI-60 mean log GI ₅₀	-5.8	-5.7	-6.1

significantly better; the corresponding value for NMS-873's solubility is 86 μ M, and its metabolic half-life is <10 min in both HLM and MLM. The improvement in properties for the phenyl indoles has facilitated biophysical studies (e.g., cryo-EM analyses) with these compounds that were not feasible with NMS-873. Another key difference between this series of inhibitors and NMS-873 appears to be the nature of the allosteric inhibition. While NMS-873 exhibits mostly non-competitive inhibition,⁹ the phenyl indoles, as a class, are uncompetitive inhibitors.^{15,16}

We then evaluated whether compounds inhibited p97-dependent activities in cells. In an assay that measured accumulation of a ubiquitinated substrate,^{21–23} 17 and 23 showed modest effects at 1 h (EC₅₀ = 19 and 15 μ M, respectively), but the effect was not observed at 6 h even at 40 μ M. In contrast, NMS-873 showed robust effects at both 1 and 6 h (EC₅₀ = 1.42 and 2.06 μ M, respectively) (Table 2). We considered several hypotheses to explain this lack of correlation between biochemical activity (ATPase) and cellular activity (ubiquitin-mediated degradation). MDCK permeability measurements were uninterpretable, but poor cellular penetration was considered unlikely based on the high intracellular concentrations measured for representative analogs (including 14; data not shown).²⁴ A second possibility was that the uncompetitive mechanism of the phenyl indole inhibitors was not as efficacious as ATP-competitive (such as CB-5083) or noncompetitive (such as NMS-873) mechanisms at blocking p97's unfoldase activity.^{15,25–27} Finally, an intriguing possibility is that the Ub^{G76V}-GFP cellular assay does not recapitulate all of the diverse functions of p97 and that this phenyl indole class selectively inhibits only certain p97-dependent functions, such as autophagy. We have started to evaluate whether other p97-dependent cellular activities are affected by these phenyl indoles. Preliminary data suggests this may be the case; these results will be reported in due course.¹⁵

Consistent with blockade of p97, 17 and 23 inhibited cell growth in the NCI-60 cell line panel.²⁸ Both demonstrated broad activity in leukemia (pGI₅₀ = -5.7 to -6.7 for 17 and 23); NSCL cancer (pGI₅₀ = -5.7 to -6.0 for 17; -5.7 to -5.8 for 23); colon cancer (pGI₅₀ = 5.8 to -6.4 for 17; 5.8 to -6.3 for 23); CNS tumor (pGI₅₀ = -5.7 to -5.8 for 17 and 23); melanoma (pGI₅₀ = -5.7 to -5.9 for 17; -5.7 to -6.5 for 23); ovarian cancer (pGI₅₀ = -5.7 to -5.8 for 17 and 23); renal cancer (pGI₅₀ = -5.7 to -5.8 for 17 and 23); prostate cancer (pGI₅₀ = -5.7 for 17; -5.7 to -5.8 for 23); and breast cancer (pGI₅₀ = -5.8 for 17; -5.7 to -5.9 for 23) cell lines (see SI).

In conclusion, by applying systematic medicinal chemistry strategies, we optimized the side-chain region of a series of 2-phenylindole p97 inhibitors. SAR studies combined with structural information and molecular modeling were used to

develop a refined binding model suitable for future analog design iterations. The most potent compounds in this series, such as 17 and 23, exhibit low nanomolar biochemical inhibition of the ATPase and excellent properties but showed variable effects in cellular assays that are commonly used to evaluate certain p97-dependent activities. However, these compounds exhibited antiproliferative effects in the NCI-60 panel in the high nanomolar to low micromolar range. Allosteric inhibitors such as 17 and 23 have the potential to be developed into novel cancer therapeutics and to be used as chemical biology tools to interrogate the function of p97 in cancer and other p97-dependent diseases. Further studies on this series of p97 inhibitors will be reported in due course.

■ ASSOCIATED CONTENT

Supporting Information

The Supporting Information is available free of charge on the ACS Publications website at DOI: 10.1021/acsmchemlett.8b00372.

Synthetic procedures and spectral data for key compounds, computational methods, biological assay protocols, NCI-60 data, and NMR spectra of final products (PDF)

■ AUTHOR INFORMATION

Corresponding Authors

*E-mail: huryn@pitt.edu.

*E-mail: pwipf@pitt.edu.

*E-mail: michelle.arkin@ucsf.edu.

ORCID

Donna M. Huryn: 0000-0001-5542-4968

Author Contributions

The manuscript was written through contributions of all authors. All authors have given approval to the final version of the manuscript.

Funding

The project was funded in whole or in part with federal funds from the National Cancer Institute, National Institutes of Health, under Chemical Biology Consortium Contract No. HHSN261200800001E, Agreement No. 29XS127TO15.

Notes

The authors declare no competing financial interest.

Biographies

Michelle Arkin is a Professor in Pharmaceutical Chemistry, co-Director of the UCSF Small Molecule Discovery Center (SMDC), and an Adjunct Professor at the Buck Institute for Aging Research. Her research focuses on developing probes and drug leads that modulate allosterically regulated enzymes and protein-protein interactions (PPI). Michelle is the current President of the BOD for the Academic Drug Discovery Consortium, PI for UCSF in the NCI Chemical Biology Consortium, and editorial board member for the Assay Guidance Manual and Current Protocols in Chemical Biology. Prior to UCSF, Michelle worked at Sunesis Pharmaceuticals, where she helped discover inhibitors of PPI, including IL-2 and LFA-1 (liftigrast; SARcode/Shire).

Peter Wipf received his Ph.D. in Chemistry from the University of Zürich, where he worked in the group of Prof. Heinz Heimgartner on synthetic transformations of 3-amino-2*H*-azirines. He then joined the laboratory of Prof. Robert E. Ireland at the University of Virginia as a Swiss NSF postdoctoral fellow on the total synthesis of FK-506. In 1990, he moved to the University of Pittsburgh, where, since 2004, he

holds the rank of Distinguished University Professor. His group works on natural products total synthesis and also pursues a diverse but always challenging range of projects in heterocyclic, medicinal, and computational chemistry.

Donna M. Huryn received her Ph.D. in Organic Chemistry from the University of Pennsylvania and began her career as a medicinal chemist in the pharmaceutical industry (Hoffmann-La Roche & Wyeth Research), where she contributed to drug discovery efforts for HIV, cancer, asthma, and CNS disorders. In 2004, she joined academia, and is now Professor at the University of Pittsburgh School of Pharmacy and holds an adjunct appointment in the Chemistry Department at the University of Pennsylvania. Her research focuses on the design and synthesis of small molecule probes and drugs to treat cancer, acute kidney injury, and neurodegenerative disorders.

ACKNOWLEDGMENTS

The authors gratefully acknowledge Marina Kovaliov (University of Pittsburgh) for technical support and advice; Chaemin Lim (University of Pittsburgh) for data retrieval and collation; Mary Liang (University of Pittsburgh) for compound management and extensive assistance with manuscript preparation; Taber Maskrey (University of Pittsburgh) for analytical chemistry support; Clifford Bryant (UCSF) for preliminary chemistry; Gregory Lee (UCSF) for help with data compilation; Sean Marcisin, CTP US Army; Jason Sousa and Brittney Potter (WRAIR) for solubility data; AMRI for microsomal stability data; Richard Gussio, CAPT USPHS (NCI) for contributions to computational and molecular modeling studies; and the NCI for access to the NCI-60 cell line. The authors also appreciate the helpful discussion and suggestions of all the CBC p97 project team members, particularly Raymond Deshaies (CalTech), Eric Baldwin (Leidos), Andrew Flint (Leidos), Barbara Mroczkowski (NCI), Shizuko Sei (Leidos), Gordon Stott (Leidos), Gunda Georg (University of Minnesota), and Michael Walters (University of Minnesota).

ABBREVIATIONS

AAA+, ATPase associated with diverse activities; CLogP, calculated logP; CNS, central nervous system; cryo-EM, cryo electron microscopy; dba, dibenzylideneacetone; CyJohnPhos, (2-biphenyl)dicyclohexylphosphine; GI₅₀, growth inhibition 50%; HLM, human liver microsomes; IC₅₀, inhibitory concentration 50%; MLM, mouse liver microsomes; NSCL, nonsmall cell lung; PDE6, phosphodiesterase 6; tPSA, total polar surface area; Ub^{G76V}-GFP, ubiquitin Gly76 to Val-green fluorescent protein

REFERENCES

- (1) Xia, D.; Tang, W. K.; Ye, Y. Structure and function of the AAA+ ATPase p97/Cdc48p. *Gene* **2016**, *583* (1), 64–77.
- (2) van den Boom, J.; Meyer, H. VCP/p97-Mediated Unfolding as a Principle in Protein Homeostasis and Signaling. *Mol. Cell* **2017**, *69*, 182–194.
- (3) Chapman, E.; Maksim, N.; de la Cruz, F.; La Clair, J. J. Inhibitors of the AAA+ chaperone p97. *Molecules* **2015**, *20* (2), 3027–3049.
- (4) Ding, R.; Zhang, T.; Xie, J.; Williams, J.; Ye, Y.; Chen, L. Eeyarestatin I derivatives with improved aqueous solubility. *Bioorg. Med. Chem. Lett.* **2016**, *26* (21), 5177–5181.
- (5) Tao, S.; Tillotson, J.; Wijeratne, E. M.; Xu, Y. M.; Kang, M.; Wu, T.; Lau, E. C.; Mesa, C.; Mason, D. J.; Brown, R. V.; La Clair, J. J.; Gunatilaka, A. A.; Zhang, D. D.; Chapman, E. Withaferin A Analogs That Target the AAA+ Chaperone p97. *ACS Chem. Biol.* **2015**, *10* (8), 1916–1924.

- (6) Chou, T. F.; Li, K.; Frankowski, K. J.; Schoenen, F. J.; Deshaies, R. J. Structure-activity relationship study reveals ML240 and ML241 as potent and selective inhibitors of p97 ATPase. *ChemMedChem* **2013**, *8* (2), 297–312.

- (7) Magnaghi, P.; D'Alessio, R.; Valsasina, B.; Avanzi, N.; Rizzi, S.; Asa, D.; Gasparri, F.; Cozzi, L.; Cucchi, U.; Orrenius, C.; Polucci, P.; Ballinari, D.; Perrera, C.; Leone, A.; Cervi, G.; Casale, E.; Xiao, Y.; Wong, C.; Anderson, D. J.; Galvani, A.; Donati, D.; O'Brien, T.; Jackson, P. K.; Isacchi, A. Covalent and allosteric inhibitors of the ATPase VCP/p97 induce cancer cell death. *Nat. Chem. Biol.* **2013**, *9* (9), 548–556.

- (8) Polucci, P.; Magnaghi, P.; Angiolini, M.; Asa, D.; Avanzi, N.; Badari, A.; Bertrand, J.; Casale, E.; Cauteruccio, S.; Cirila, A.; Cozzi, L.; Galvani, A.; Jackson, P. K.; Liu, Y.; Magnuson, S.; Magnesini, B.; Nuvoloni, S.; Orrenius, C.; Sirtori, F. R.; Riceputi, L.; Rizzi, S.; Trucchi, B.; O'Brien, T.; Isacchi, A.; Donati, D.; D'Alessio, R. Alkylsulfanyl-1,2,4-triazoles, a new class of allosteric valosine containing protein inhibitors. Synthesis and structure-activity relationships. *J. Med. Chem.* **2013**, *56* (2), 437–450.

- (9) Alvarez, C.; Bulfer, S. L.; Chakrasali, R.; Chimenti, M. S.; Deshaies, R. J.; Green, N.; Kelly, M.; LaPorte, M. G.; Lewis, T. S.; Liang, M.; Moore, W. J.; Neitz, R. J.; Peshkov, V. A.; Walters, M. A.; Zhang, F.; Arkin, M. R.; Wipf, P.; Huryn, D. M. Allosteric Indole Amide Inhibitors of p97: Identification of a Novel Probe of the Ubiquitin Pathway. *ACS Med. Chem. Lett.* **2016**, *7* (2), 182–187.

- (10) Zhou, H. J.; Wang, J.; Yao, B.; Wong, S.; Djakovic, S.; Kumar, B.; Rice, J.; Valle, E.; Soriano, F.; Menon, M. K.; Madriaga, A.; Kiss von Soly, S.; Kumar, A.; Parlati, F.; Yakes, F. M.; Shawver, L.; Le Moigne, R.; Anderson, D. J.; Rolfe, M.; Wustrow, D. Discovery of a First-in-Class, Potent, Selective, and Orally Bioavailable Inhibitor of the p97 AAA ATPase (CB-5083). *J. Med. Chem.* **2015**, *58* (24), 9480–9497.

- (11) Anderson, D. J.; Le Moigne, R.; Djakovic, S.; Kumar, B.; Rice, J.; Wong, S.; Wang, J.; Yao, B.; Valle, E.; Kiss von Soly, S.; Madriaga, A.; Soriano, F.; Menon, M. K.; Wu, Z. Y.; Kampmann, M.; Chen, Y.; Weissman, J. S.; Aftab, B. T.; Yakes, F. M.; Shawver, L.; Zhou, H. J.; Wustrow, D.; Rolfe, M. Targeting the AAA ATPase p97 as an Approach to Treat Cancer through Disruption of Protein Homeostasis. *Cancer Cell* **2015**, *28* (5), 653–665.

- (12) <https://deainfo.nci.nih.gov/advisory/fac/0518/Doroshov.pdf> (accessed August 2, 2018).

- (13) Alvarez, C.; Arkin, M. R.; Bulfer, S. L.; Colombo, R.; Kovaliov, M.; LaPorte, M. G.; Lim, C.; Liang, M.; Moore, W. J.; Neitz, R. J.; Yan, Y.; Yue, Z.; Huryn, D. M.; Wipf, P. Structure-Activity Study of Bioisosteric Trifluoromethyl and Pentafluorosulfanyl Indole Inhibitors of the AAA ATPase p97. *ACS Med. Chem. Lett.* **2015**, *6* (12), 1225–1230.

- (14) Burnett, J. C.; Lim, C.; Peyser, B. D.; Samankumara, L. P.; Kovaliov, M.; Colombo, R.; Bulfer, S. L.; LaPorte, M. G.; Hermone, A. R.; McGrath, C. F.; Arkin, M. R.; Gussio, R.; Huryn, D. M.; Wipf, P. A threonine turnstile defines a dynamic amphiphilic binding motif in the AAA ATPase p97 allosteric binding site. *Org. Biomol. Chem.* **2017**, *15* (19), 4096–4114.

- (15) Manuscript in preparation.

- (16) Banerjee, S.; Bartesaghi, A.; Merk, A.; Rao, P.; Bulfer, S. L.; Yan, Y.; Green, N.; Mroczkowski, B.; Neitz, R. J.; Wipf, P.; Falconieri, V.; Deshaies, R. J.; Milne, J. L.; Huryn, D.; Arkin, M.; Subramaniam, S. 2.3 Å resolution cryo-EM structure of human p97 and mechanism of allosteric inhibition. *Science* **2016**, *351* (6275), 871–875.

- (17) Kuehne, M. E.; Kitagawa, T. Reactions of indoles with benzyne. *J. Org. Chem.* **1964**, *29*, 1270–1273.

- (18) Ruiz-Castillo, P.; Buchwald, S. L. Applications of Palladium-Catalyzed C-N Cross-Coupling Reactions. *Chem. Rev.* **2016**, *116*, 12564–12649.

- (19) Kumpaty, H. J.; Bhattacharyya, S.; Rehr, E. W.; Gonzalez, A. M. Selective Access to Secondary Amines by a Highly Controlled Reductive Mono-N-Alkylation of Primary Amines. *Synthesis* **2003**, 2206–2210.

- (20) Recently, a series of indoles containing a basic side chain was reported to allosterically inhibit p97 at the same site; the potency of this

series was in the low micromolar range. Pöhler, R.; Krahn, J. H.; van den Boom, J.; Dobrynin, G.; Kaschani, F.; Eggenweiler, H. M.; Zenke, F. T.; Kaiser, M.; Meer, H. A non-competitive inhibitor of VCP/p97 and VPS4 reveals conserved allosteric circuits in type I and II AAA ATPases. *Angew. Chem., Int. Ed.* **2018**, *57* (6), 1576–1580.

(21) Dantuma, N. P.; Lindsten, K.; Glas, R.; Jellne, M.; Masucci, M. G. Short-lived green fluorescent proteins for quantifying ubiquitin/proteasome-dependent proteolysis in living cells. *Nat. Biotechnol.* **2000**, *18*, 538–543.

(22) Dantuma, N. P.; Lindsten, K.; Glas, R.; Jellne, M.; Masucci, M. G. Screening assay for compounds targeting the p97 AAA-ATPase complex in the ubiquitin proteasome system. WO 2010003908.

(23) Chou, T. F.; Brown, S. J.; Minond, D.; Nordin, B. E.; Jones, A. C.; Chase, P.; Porubsky, P. R.; Stoltz, B. M.; Schoenen, F. J.; Patricelli, M. P.; Hodder, P.; Rosen, H.; Deshaies, R. J. Reversible inhibitor of p97, DBE-Q, impairs both ubiquitin-dependent and autophagic protein clearance pathways. *Proc. Natl. Acad. Sci. U. S. A.* **2011**, *108*, 4834–4839.

(24) Assays performed by Quintara Biosciences: briefly, cells are treated with compounds at varying concentrations. After incubation and removal of supernatant, cells are lysed and compound concentrations quantified by LC/MS/MS.

(25) Bodnar, N. O.; Rapoport, T. A. Molecular mechanism of substrate processing by the Cdc48 ATPase complex. *Cell* **2017**, *169*, 722–735.

(26) Blythe, E. E.; Olson, K. C.; Chau, V.; Deshaies, R. J. Ubiquitin- and ATP-dependent unfoldase activity of p97/VCP-NPLOC4-UFD1L is enhanced by a mutation that causes multisystem proteinopathy. *Proc. Natl. Acad. Sci. U. S. A.* **2017**, *114*, E4380–E4388.

(27) The uncompetitive mechanism of **17** and **23** is inferred from the cryo-EM costructure of **14** and preliminary data for **23** in ATPase assays.

(28) Shoemaker, R. H. The NCI60 human tumor cell line anticancer drug screen. *Nat. Rev. Cancer* **2006**, *6*, 813–23.